

Supplementary Figure 3. PD1 inhibition enhances survival benefit of CAR T treatment in KHM-5M xenografts.

(A) E:T assays were carried out with CAR T-1 and NT cells alone or with combination of anti-PD1 antibody (5 µg/ml) (*n* = 3; #, *P* = 0.06 for KHM-5M, 0.054 for 8505C; *, *P* < 0.05; ****, *P* < 0.0001 by one-way ANOVA test). The analysis was independently repeated at least two times.
(B) Survival curve of animals with KHM-5M xenografts with various treatments and no treatment is shown (*n* = 4 for all groups except for CAR T_{hi} group, which is *n* = 3; *, *P* < 0.05 by the log-rank test). NSG mice with KHM-5M xenografts were established with injecting $0.5x10_6$ cells intravenously. CAR T_{hi} group was injected with $5x10_6$ ICAM1-CAR T (mAS) cells. CAR T_{lo} group was treated with $0.75x10_6$ CAR T cells either with anti-PD1 antibody administration (+) or alone (-). Administration of CAR T (i.v.) and αPD1 antibody (i.p.) started ~5 days after xenograft. CAR T was a single treatment, while αPD1 antibody (150 µg/mouse) administration was twice a week for 5 weeks.